Olon Corporate Governance Contact us Work with us Home Group Company Products Custom & Contract Manufacturing Facilities R&D ABOUT US: Olon S.p.A. is a worldwide leader in the development and production of APIs (Active Pharmaceutical Ingredients). The ideal partner for custom synthesis and contract manufacturing projects. NEWS & EVENTS: June 9th, 2017 - OLON acquired RICERCA [read more...] CPhI Worldwide, Frankfurt 24-26 October 2017 – Visit us at Booth # 80G51 May 19th, 2016 - OLON acquired INFA Group [read more...] PRODUCTS SEARCH: All Commercial R&D Therapeutic class Agents for Multiple Sclerosis Alcohol dependence treatment Amoebicide Analgesic Anorectic Anti-Alzheimer Anti-inflammatory Anti-Parkinson Antiacne Antiallergic Antiandrogen Antianginal Antiarthritic Antiasthmatic Antibacterial Antibiotic Antibiotic (Tuberculosis) Antidepressant Antidiabetic Antidiarrheal Antiemetic Antiepileptic Antiglaucoma Antihelmintic Antihistaminic Antihypertensive Antilipemic Antimalarial Antimicotic Antimigraine Antineoplastic Antineoplastic antibiotic Antineoplastic; antiacne Antineoplastic; Antipsoriatic Antiosteoporotic Antioxidant Antiprotozoal Antipsoriatic Antipsoriatic; Antiacne Antipsychotic Antiseptic Antispasmodic Antithrombotic Antitussive Antivertigo Antiviral Antiviral (HIV) Bronchodilator Bronchodilator (COPD) Chelating agent Contraceptive (oral) Coronary vasodilator Diabetic neuropathy Diuretic Exclusive parenteral nutrition Hair growth stimulant Hepatoprotectant Lipoprotein disorders Mucolytic Neuroleptic Other Postmenopausal treatment Vasodilator Search FOCUS ON: OLAPARIB Olon S.p.A. is going to finalise its development of API OLAPARIB. The product is a poly-ADP-Ribose polymerase inhibitor and it is used for the treatment of ovarian cancer. NINTEDANIB Olon S.p.A. is going to finalise its development of API NINTEDANIB. The product is an angiogenesis inhibitor and it is used for the treatment of idiopathic pulmonary fibrosis (IPF). NINTEDANIB will join other cytotoxics for cancer therapy already in our portfolio, such as clofarabine, irinotecan, tofacitinib citrate. Olon S.p.A. Società con Socio unico Strada Rivoltana km 6/7 | 20090 Rodano (Milano) | ITALY Phone: +39 02 95 231 E-mail: info@olonspa.it P.IVA 08101100157 ~ Capitale Sociale € 40.000.000 i.v. ~ R.E.A. Milano n. 1201640 Privacy policy | Cookie policy Sintattica web design By continuing to use our website, you consent to the usage of cookies as described in our Cookie Policy.more informationsOK